CXL

Corneal cross-linking (CXL) is a curative approach to re-increase the mechanical stability of corneal tissue that is progressively decreasing as a result of corneal disease such as keratoconus or pellucid marginal degeneration. The procedure was developed by IROC co-founder Prof. Theo Seiler together with Prof. Eberhard Spoerl from Dresden. CXL treatment has proven its safety and effectiveness in clinical use for many years now. 

CXL creates additional chemical bonds inside the weakened corneal stroma by means of highly localized photo-polymerisation. Consequently, the biomechanical stability of the tissue is re-increased and corneal transplantation can be avoided. 

 

Learn more about CXL:

Newsflash

Meet us at 2013 Congress

Meet Prof. Dr. Michael Mrochen, CEO of IROC Innocross AG @ ASCRS San Francisco, DOC in Nürnberg, ESCRS in Amsterdam, CXL in Dublin

Read more …

NOW AVAILABLE: UV-X 2000

The new UV-X beam optimized illumination system is the first device that features an optimized beam profile to maximize the cross-linking volume.

Read more …

Quality Management

IROC is certified according to EN ISO 13485:2003 & MDD 93/42/EEC Annex II

Read more …